Glycated albumin levels are higher relative to glycated haemoglobin levels in gastrectomized subjects.
ABSTRACT In gastrectomized subjects, oral glucose tolerance test often shows marked hyperglycaemia (oxyhyperglycaemia) after glucose loading. Because serum glycated albumin (GA) has been shown to better reflect postprandial and maximum plasma glucose levels, we investigated whether or not the clinical significance of serum GA and glycated haemoglobin (HbA(1C)) in non-diabetic gastrectomized subjects differs.
During health examinations, 62 non-diabetic subjects with a history of gastrectomy and 87 non-diabetic control subjects were selected in the present study. Body mass index (BMI) in the gastrectomy group was significantly lower than in the control group.
Fasting plasma glucose levels were significantly lower in the gastrectomized subjects than in the control subjects. Although both HbA(1C) and serum GA were significantly higher in the gastrectomized subjects, there was a significant difference in GA/HbA(1C) ratio between the gastrectomized subjects and the control subjects. BMI-adjusted serum GA, based on our previous finding of inverse influence of BMI on serum GA, was also significantly higher in the gastrectomized subjects than in the controls.
Serum GA is higher relative to HbA(1C) in gastrectomized subjects. This suggests that serum GA may be a better marker than HbA(1C) for glycaemic excursion in these subjects.
[show abstract] [hide abstract]
ABSTRACT: The conventional glycemic indices used in management of diabetic patients includes A1c, fructosamine, 1,5-anhydroglucitol, and glycated albumin (GA). Among these indices, A1c is currently used as the gold standard. However, A1c cannot reflect the glycemic change over a relatively short period of time, and its accuracy is known to decrease when abnormalities in hemoglobin metabolism, such as anemia, coexist. When considering these weaknesses, there have been needs for finding a novel glycemic index for diagnosing and managing diabetes, as well as for predicting diabetic complications properly. Recently, several studies have suggested the potential of GA as an intermediate-term glycation index in covering the short-term effect of treatment. Furthermore, its role as a pathogenic protein affecting the worsening of diabetes and occurrence of diabetic complications is receiving attention as well. Therefore, in this article, we wanted to review the recent status of GA as a glycemic index and as a pathogenic protein.Diabetes & metabolism journal 04/2012; 36(2):98-107.